Pharmacodynamics. Taufon refers to preparations of amino acids that stimulate reparative and regenerative processes in diseases of the retina of the eye of a dystrophic nature, traumatic lesions of the eye, pathological processes that are accompanied by a sharp violation of the metabolism of these tissues. as a compound containing sulfur, the preparation helps to normalize the functions of cell membranes, optimize energy and metabolic processes, maintain a constant electrolyte composition of the cytoplasm of cells, inhibit synaptic transmission (neurotransmitter role).
Pharmacokinetics. When instilled, Taufon penetrates into the tissues of the eye, where it has its specific effect. When used in therapeutic doses, the preparation is practically not absorbed into the systemic circulation.
Dystrophic lesions of the cornea and retina, including hereditary tapetoretinal degenerations; senile, diabetic, traumatic and radiation cataracts; as a means of stimulating reparative processes in corneal injuries; as an additional agent in the treatment of open-angle glaucoma.
Taufon is prescribed for adults.
For the treatment of cataracts, 2-3 drops are prescribed 2-4 times a day. The course of treatment is 3 months. Repeat the course with an interval of 1 month.
In case of injuries, apply 2-3 drops 2-4 times a day for 1 month.
For the treatment of tapetoretinal degeneration and other degenerative diseases of the retina, penetrating corneal injuries, the preparation is administered under the conjunctiva, 0.3 ml of 4% solution once a day for 10 days. Repeat the course of treatment after 6–8 months.
In case of open-angle glaucoma, Taufon is instilled 2-3 drops into the conjunctival sac 2 times a day 20-30 minutes before using timolol. The course of treatment is determined individually.
Hypersensitivity to the preparation and its components.
The preparation is generally well tolerated. some patients may develop allergic reactions, conjunctival hyperemia, itching, burning and cramps in the eyes.
In open-angle glaucoma, the preparation is used in combination with timolol 20-30 minutes before instillation of timolol.
Application during pregnancy or lactation. The efficacy and safety of use during pregnancy or lactation have not been studied.
Children. The efficacy and safety of use in children have not been studied.
The ability to influence the reaction rate when driving or working with other mechanisms. Has not been studied.
When combined with timolol eye drops, a potentiated decrease in intraocular and arterial pressure is observed.
Overdose cases are not described.
In the dark place at a temperature of 8-15 ° c.
There are no reviews for this product.